Literature DB >> 15351914

From the magic bullet to an effective therapy: the peptide experience.

Luigi Mansi.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15351914     DOI： 10.1007/s00259-004-1661-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  26 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

2.  Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities?

Authors:  Renato A Valdés Olmos; Cornelis A Hoefnagel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-23       Impact factor: 9.236

3.  Translational research using the sodium/iodide symporter in imaging and therapy.

Authors:  June-Key Chung; Joo Hyun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-10       Impact factor: 9.236

4.  Intraoperative detection of lung cancer by octreotide labeled to Indium-111.

Authors:  V Pastore; E Di Lieto; L Mansi; P F Rambaldi; M Santini; R Mancusi
Journal:  Semin Surg Oncol       Date:  1998-12

5.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.

Authors:  H J Wester; M Schottelius; K Scheidhauer; G Meisetschläger; M Herz; F C Rau; J C Reubi; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-05       Impact factor: 9.236

6.  Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.

Authors:  Sylvie Froidevaux; Alex N Eberle; Martine Christe; Lazar Sumanovski; Axel Heppeler; Jörg S Schmitt; Klaus Eisenwiener; Christoph Beglinger; Helmut R Mäcke
Journal:  Int J Cancer       Date:  2002-04-20       Impact factor: 7.396

Review 7.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

8.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

9.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

Authors:  M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke
Journal:  Eur J Nucl Med       Date:  1997-04

10.  99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.

Authors:  Michael Gabriel; Clemens Decristoforo; Theodosia Maina; Berthold Nock; Elisabeth vonGuggenberg; Paul Cordopatis; Roy Moncayo
Journal:  Cancer Biother Radiopharm       Date:  2004-02       Impact factor: 3.099
View more
  1 in total

1.  Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Shuren Li; Bettina Ibi; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-21       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.